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Abstract
The development of robust, non-hypothesis based case/control studies has led to a large push forward towards
identifying common genetic variants that contribute to complex traits. However, despite many attempts, the
search for common disease-predisposing variants in childhood developmental disorders has largely failed. Recently,
a role for rare causal variants and de novo mutations is emerging in the genetic architecture of some of these
disorders, particularly those that incur a large degree of selection against the phenotype. In this paper, we examine
these data and use classic genetic epidemiological approaches to gain insights into the genetic architecture of
ASD. Future studies using next generation sequencing should elucidate the precise role de novo mutations play in
disorders traditionally thought to have resulted from polygenic or common disease, common variants inheritance.
Introduction
Autistic spectrum disorders (ASD) are a group of neuro-
developmental disorders clinically characterized by deficits
i nt h r e ec o r ed o m a i n st e r m e dt h ep h e n o t y p i ct r i a d :
impairments in social interaction; impairments in commu-
nication; and restricted interests and repetitive behavior.
The group consists of Asperger’s syndrome (AS), pervasive
developmental disorder not otherwise specified (PDD-
NOS) and the prototypical autistic disorder (AD). They all
share a similar age of onset of approximately 12 to 36
months, which corresponds to the developmental time
period when spatial and temporal transcriptional cascades
lead to remodeling and elaboration of neuronal circuitry
[1,2]. The prevalence of ASD is between 10 in 10,000 and
60 to 70 in 10,000, depending on the precise definition
used [3]. Evidence from family studies implies that ASD
has a strong genetic basis: the concordance rate in mono-
zygotic (MZ) twins ranges from 70 to 90%, whereas dizy-
gotic (DZ) twin concordance varies from 0 to 10% [4,5].
Familial aggregation studies have shown that the relative
risk of developing autism in first-degree relatives of an
autistic patient is 3 to 7%, which is ten-fold higher than
the prevalence in the general population. Although these
lines of evidence suggest that the disorder is primarily of
genetic origin, the genetic susceptibility factors responsible
for ASD have remained largely elusive, despite several
recent advancements in the field.
Despite the seemingly precise definition of ASD above, it
must be understood that ASD is not necessarily a simple
binary diagnosis. ASD is a grouping of childhood develop-
mental disorders that reflect the difficulties in categorizing
psychiatric disorders on the background of a shifting land-
scape of child development, neuroplasticity and historical
nosology, which do not necessarily reflect a homogenous
grouping of phenotypes with shared genetic characters on
the underlying biological level. ASD has a wide clinical
spectrum, with some individuals being high-functioning
college students with above-average IQs [6], a fraction
being able to perform astonishing memory feats and calcu-
lations [7], and others being non-verbal with severe mental
retardation, involving self-injury [8]. Comorbidity with epi-
lepsy is estimated at approximately 30% [9,10], while a
strict definition of macrocephaly is seen in approximately
20% of children diagnosed with ASD [11].
Although recent studies have highlighted that de novo
mutations and copy-number variations (CNVs) may be
involved in a significant proportion of ASD cases [12-21],
identifying whether the remaining cases of idiopathic
ASD result from common variants with low effect sizes
or rare variants/de novo mutations with high penetrance
is important to help direct and guide future research and
funding efforts aimed at gene identification. Although
obtaining precise, multigenerational genome-wide
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possible to examine the empirical data that are directly
influenced by the underlying genetic architecture to
deduce the potential contributions that de novo muta-
tions may provide to the overall proportion of idiopathic
ASD cases.
It has been well established that large-scale de novo
chromosomal anomalies frequently occur in patients
with ASD, explaining approximately 5 to 10% of cases
[22,23], including reports showing a strong association
with de novo CNVs [18]. It is also believed that techni-
ques providing higher resolution of CNVs will probably
identify smaller de novo CNVs responsible for an even
higher overall proportion of ASD cases [24].
To date, the mutations discovered in genes that have
been associated with high penetrance and risk for display-
ing the ASD phenotype are those that have arisen de novo
with limited transmission, as reviewed previously [25]. In
terms of function, 13 of 26 high-risk high-penetrance
mutations have been discovered in genes expressed at the
synapse [25]. Others have also been described in transcrip-
tion factors expressed in the fetal brain (in the case of ARX
[26]), genes involved in translational repression by RNA
binding (in the case of FMR1, the gene responsible for fra-
gile X syndrome[27-29]), and in tumor suppressor genes
(for example, TSC1 and TSC2) [28,30,31]. Although there
a higher proportion of mutations have been found in
genes expressed at the synapse, the results do not indicate
a convergence on any particular pathway or molecular
machinery that will homogenously distinguish patients
currently labeled on the phenotypic level with ASD.
Therefore, ASD represents monogenic dysfunction in a
vast array of molecular pathways and functional structures,
all leading to the same general phenotype, implicating pos-
sibly hundreds of potential candidate genes. For example,
using conservative numbers, there are approximately 3,000
genes expressed at the synapse that contribute to synaptic
function. Countless more are brain-expressed embryonic
transcription factors, translational repressors and tumor
suppressors. Certainly, mutations in all of these candidate
genes and their downstream targets are unlikely to pro-
duce the ASD phenotype; however, there is clearly a
potential for the same phenotype to arise as a result of
monogenic mutations in any one of several hundred
genes.
Although not all amino acid substitutions will have a
functional effect, a significant fraction will lead to disease.
It has been estimated that in every zygote, there are
approximately 1 to 3 new deleterious mutations that lead
to an altered amino acid per genome, this is on average 1
new mutation per 10,000 genes/zygote [19,32]. Therefore,
for a disease such as ASD that may result from dysfunc-
tion in any one of hundreds of different genes, new muta-
tions may be responsible for a significant fraction of
cases. Examining conditions for which genes have pre-
viously been identified, it is evident that new mutations
are common. For example, 1 in 6,000 live births harbor a
novel mutation causing neurofibromatosis type 1 (NF1)
[33,34]. The frequency of new point mutations in Duch-
enne muscular dystrophy is similar: 1 in 10,500 live births
[35]. These are large genes allowing for a high mutation
rate; however, their total genomic size is a small fraction
compared with the genomic size of the hundreds of
potential genes that may all produce the same general
ASD phenotype. The estimated mutation rate of a repeti-
tive stretch of genomic DNA is approximately 100,000
times more frequent than common point mutations [36].
These stretches can code for poly-amino acid tracts,
which are found in hundreds of genes throughout the
genome, or for regulatory elements such as FMR1. For
example, alanine tract expansions in the ARX gene, a
transcription factor expressed in the fetal brain, produces
a broad spectrum of disorders including epilepsy, mental
retardation and the ASD phenotype [26,37]. In the case
of FMR1, an expansion of the repeat within the upstream
regulatory region leads to hypermethylation and silenced
gene expression [38]. Given the ubiquitous presence of
repetitive stretches of DNA within coding regions or reg-
ulatory genetic elements, de novo expansions or contrac-
tions of these repetitive elements could account for a
fraction of ASD cases as well.
Taken together, these above examples show that de
novo mutations could potentially occur with a suffi-
ciently high frequency to explain the relatively high inci-
dence of ASD, and act dominantly to do so. Mutations
in known genes for ASD currently explain only a small
fraction of cases. Under a model dominated by de novo
mutations, over time more monogenic mutations should
be discovered in different genes, each contributing a
small portion of the overall disease incidence. The ques-
tion is whether a model such as this can be reconciled
with all of the data gleaned from genetic epidemiologists
to account for the genetic architecture of ASD.
One of the predictions of an architecture dominated by
de novo mutations implies that individuals diagnosed
with ASD are at increased risk for a recurring phenotype
in their children, owing to the transmission of the
recently arisen dominant mutation. Although such a
study is difficult to undertake, given the low reproductive
rate of individuals with ASD, a study investigated this
prediction by examining multiplex families with idio-
pathic forms of ASD from the Autism Genetic Resource
Exchange (AGRE) database [12]. They found that families
with unidentified mutations can be grouped into two
types: a small minority for whom the risk of autism in
male offspring is near 50%, and the vast majority, for
whom male offspring have a low risk. They proposed that
sporadic autism in the low-risk families is mainly caused
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in males and relatively poor penetrance in females. They
explained that those high-risk families include offspring,
most often unaffected females, who carry a new domi-
nant mutation, and in turn transmit the mutation to
their offspring. Obviously, by looking at cases in multi-
plex families, which represent a small fraction of all cases
of autism, these conclusions cannot be generalized. A
more relevant study, looking at the children of sporadic
cases of autism, has not been reported.
Twin studies and sibling recurrence
As mentioned above, the MZ twin concordance rate for
ASD is 70 to 90% and the DZ concordance is similar to
the sibling recurrence rate of 0 to 10%, with the extreme
values probably being representative of smaller sample
sizes [4,5,39]. Given these numbers, there are two possi-
ble explanations for the data: a polygenic model invol-
ving several genes interacting with environmental
factors, or de novo mutations with limited transmission.
Most de novo mutations will occur in affected indivi-
duals and will not be transmitted; however, they can be
transmitted from unaffected parents to multiple affected
siblings as a result of maternal transmission of muta-
tions on the X chromosome to male offspring [40,41] or
of gonadal mosaicism [24,42], which together would
result in higher sibling recurrence rates. Furthermore, it
is also theoretically possible for transmission to occur
from asymptomatic parents via autosomal recessive
inheritance patterns or through mutations in imprinted
genes. Although features of ASD have been identified in
other syndromic epigenetic disorders [43], ASD-specific
examples of highly penetrant genetic variants whose
transmission was enabled by unaffected family members
via imprinting have yet to be discovered.
Although perfect concordance between autistic MZ
t w i n si sn o ts e e n ,t h i sd o e sn o tn e c e s s a r i l yi m p l yt h a t
environmental factors must p l a yar o l ei np r o d u c i n go r
preventing the ASD phenotype. Discordance could
occur as a result of variable X-linked inactivation [44],
somatic mosaicism for a de novo mutation that occurred
early in development in only one of the two developing
zygotes, or autosomal dominance with variable expres-
sivity, potentially resulting from stochastic events during
embryogenesis.
Association studies/linkage studies
To date, there have been three major genome-wide asso-
ciation studies (GWAS) aimed at identifying common var-
iants that predispose to ASD. The initial study investigated
780 families (3101 subjects) and a second cohort with
1204 affected individuals (all of European ancestry) and
identified significant association of six single-nucleotide
polymorphisms (SNPs) with ASD to chromosome 5p14,
an intergenic region between cadherins 9 and 10. These
genes are involved in neuronal cell adhesion, and could be
viewed as promising candidates [45]. The second study
involved a combined linkage and association study of 1031
families. Although no promising linkage results were dis-
covered, an association to an SNP near the gene SEMA5A
was shown, and this was combined with expression analy-
sis detailing decreased expression of this gene in the brains
of patients with ASD [46]. The third study, comprising
1558 individuals found genome-wide evidence for associa-
tion at the MACROD2 locus, although the authors had dif-
ficulty maintaining this signal in a replication cohort [47].
Notably, despite the robust sample sizes of these stu-
dies, none of these groups were able to replicate each
other’s results and each of the studies found modest
effect sizes ranging from 0.55 to 1.2. Furthermore, these
studies were carried out on modern platforms contain-
ing tagged SNPs for common CNVs, therefore it is also
unlikely that such CNVs will explain an appreciable
fraction of idiopathic ASD [48].
There have also been a countless number of candidate
gene association studies performed in the past, which have
suffered from the same curse of inconsistent replication.
Despite these repeated efforts, there are still no common
variants that could be inarguably associated with ASD in
the same manner in which common variants have recently
been identified for other complex traits (it should be
noted that successful association studies have generally
studied traits in which little selection occurs against the
phenotype). If the genetic architecture of ASD is domi-
nated by de novo mutations, followed by strong selection
against the phenotype, it is clear that association studies
will never identify clear signals, as these causal mutations
will never have time to establish themselves in linkage dis-
equilibrium with SNPs on a genotyping platform at a
population-wide level. However. it is theoretically possible
for an association to develop between a common variant
and a region prone to a non-homologous allelic recombi-
nation that could lead to the ASD phenotype. Although
abstract, this is not an unprecedented example [49-54].
Overall, the lack of replication in these association studies
would indicate that if common variants are still responsi-
ble for a significant fraction of idiopathic ASD, the number
of common variants involved would have to be relatively
high and their effect sizes would have to be considerably
small, as has been recently shown[55].
There have also been numerous non-parametric linkage
studies combining multiple small families, which have pro-
duced inconsistent results, with linkage peaks over the
entire genome [56,57]. The benefit of non-parametric link-
age is that this method should also identify rare variants or
transmitted mutations on different haplotypes at a small
number of loci. A problem would arise under an architec-
ture dominated by de novo mutations on a genome-wide
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genetically heterogeneous. Chromosomal regions of haplo-
type or allele sharing between siblings will be very large,
therefore highly penetrant shared haplotypes between sib-
lings could potentially be uniformly distributed through-
out the genome in any ASD cohort, resulting in random
noise during linkage analysis.
Consistent global prevalence
Obtaining global disease incidence data for ASD is diffi-
cult, as diagnostic disparities coupled with little clinical
investigation of ASD in certain regions is a hindrance.
However, studies have failed to conclusively reveal an
uneven distribution of ASD from any ethnic background
[3]. One of the many perplexing aspects of ASD is its rela-
tively high frequency and high heritability, despite strong
selection against the phenotype. This might be explained
by strong selection for disease-predisposing alleles, as is
seen for example in sickle-cell disease. However, it would
be expected that such a strong selective pressure would be
related to specific environments, which differ in different
parts of the world, and so would predict an uneven global
distribution, which is not the case for ASD. Under a poly-
genic model, this could only be reconciled by the existence
of many allelic variants with low effect sizes that confer a
susceptibility to ASD dating back to a common founder
population for all of humanity. These variants would have
had to be spread globally through small human popula-
tions as they migrated to various locations around the
world. Information gleaned from the International Hap-
map project has shown that a considerable amount of
human genetic variation is common between several
populations around the globe, indicating that a substantial
proportion of variants date back to a common founder
population [58]. Therefore, on the surface, this concept is
plausible.
In small isolated founder populations, such as those
likely to be found in many of our ancestral migratory
movements, the genetic variation is reduced, with a conco-
mitant increase in homozygosity at all loci, as founder
effects coupled with genetic drift act to reduce overall
genetic variation. This would posit that under a polygenic
model, the allelic variants that produce the ASD pheno-
type must have combined more frequently to produce
individuals that would be modernly diagnosed as autistic.
In order for these variants to have remained globally at a
similar frequency, there could not have been any selection
acting against them, or any fixation by genetic drift during
small population migrations and settlements, otherwise an
uneven disease distribution would be presently observed.
In our modern environment, autistic individuals fre-
quently survive into adulthood, yet strong negative selec-
tion still occurs against the phenotype, as evidenced by
their low reproductive rates [59]. A gene pool is a
reflection of successful reproductions between ancestral
genomes that were composed of allelic variants whose
collective actions conferred advantages to their historical
possessors. The persistence of allelic variants under nega-
tive selection throughout evolutionary history in all
human populations around the globe disagrees with evolu-
tion at the genetic level, and requires an explanation. Con-
sidering the low transmission of the ASD-conferring allelic
variants, it is thus very unlikely that the remaining cases of
idiopathic ASD could explain an even disease distribution
around the globe.
Analyzing this observed feature under the genetic
architecture of idiopathic ASD dominated by de novo
mutations, an even disease distribution would be pre-
dicted, as mutation rates should not be considerably dif-
ferent between any specific global populations.
Skewed male:female ASD ratio
It is already known that males are more prone to develop-
ing the autistic phenotype than females, by a ratio of
approximately 4:1 [60]. It has been suggested that intrinsic
differences between male and female brains may be a rea-
son why one sex is more vulnerable to the ASD variants
[61]. This explanation may apply equally well to a de novo
hypothesis as a polygenic model. A previous study high-
lighted that in high-risk families, males are more likely
than their female relatives to inherit the condition, despite
their shared genetic background [12]. The selective advan-
tage of diploidy, as a result of its protective mechanism
against de novo mutations, is intuitive, and it would there-
fore follow that hemizygous males would be prone to the
effect on the X chromosome. There is also evidence that
the X chromosome has a higher proportion of genes
involved in brain development and cognition than of auto-
somal genes [62,63]. A recent review highlighted that 6 of
26 genes that show evidence of causal, monogenic dys-
function in non-syndromic ASD are located on the X
chromosome [64], which might be considered too low a
number to fully explain the skewed sex ratio, given the
degree of scrutiny the X-chromosome has received [65].
However, it must be noted that defining the precise num-
ber of currently identified ASD alleles can be difficult,
given the degree of variable expressivity in neurodevelop-
mental disorders and the degree of clinical overlap
between ASD and other known syndromic conditions.
Using another recent review, which developed a list con-
taining every gene identified in ASD and all conditions
that currently share a clinical overlap with features of
ASD, the proportion of genes on the X chromosome was
listed at 45 of 103 [66]. Whether females are resistant to
contributing high-penetrance autosomal variants or
whether a greater proportion of X-chromosome mutations
will be discovered must be left for future research. It
should also be noted that de novo mutations occurring on
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to produce affected males, unless unfavorable X-chromo-
some inactivation produces a phenotype in females. How-
ever, it would be rare for the transmission to occur
through multiple generations, as the penetrant mutation is
unlikely to be transmitted by male offspring.
Presence of autistic features in first-degree relatives
There have been many studies showing that first-degree
relatives of individuals diagnosed with ASD can often
show some of the broader phenotypic traits of autism
[67,68]. These studies were carefully conducted with
proper controls, and were able to achieve statistical sig-
nificance consistently.
A polygenic model would nicely account for this finding,
proposing that allelic ASD variants for every autistic trait
circulate in the population. The child diagnosed with ASD
would be considered unfortunate to have acquired by
chance a higher number of these allelic variants, which
caused them to surpass the threshold in the phenotypic
triad. The existence and transmission of harmful allelic var-
iants through multiple generations has been discussed in a
previous section. It has also been suggested that the allelic
variants predisposing to the phenotypic triad are inherited
separately [69]; however, this poses a perplexing question:
how do the allelic variants predisposing to the phenotypic
triad tend to co-occur with such high frequency? The exis-
tence of numerous tightly linked haplotypes located
throughout the genome, containing clusters of ASD-
conferring allelic variants that have evaded natural selec-
tion, is unlikely. There could be an unknown mechanism
that leads to this higher than expected co-segregation, or
perhaps even a synergistic relationship between them.
However, mutations in several genes have already been dis-
covered whose global brain expression results in global def-
icits in all three domains [13,40,41,70], which questions the
necessity of investigating this avenue.
Under an architecture dominated by de novo muta-
tions, the examples of clearly identifiable, carefully con-
trolled observation of milder forms of autistic symptoms
in first-degree relatives could result from X-linked inacti-
vation in females, as well as autosomal dominant inheri-
tance with variable expressivity. X-linked inactivation will
produce a diverse array of phenotypes in female patients,
dependent on the specific location of inactivation of the
wild-type chromosome. It is easy to imagine the implica-
tions of this if stochasticity resulted in the inactivation of
the unaffected chromosome in only a portion of the
brain of female carriers. This would conceivably result in
various phenotypes, depending on the function of the
gene and the proportion and location of the expression
of the mutant copy.
Autosomal dominant mutations in genes that are
involved in embryonic development can result in an
incredibly diverse array of phenotypes. Mutations in the
Sonic Hedgehog protein (SHH), for instance, result in
holoprosencephaly, a condition whose behavioral and cog-
nitive phenotype can be similar to ASD. Mutations in this
gene can result in dramatically different phenotypes, from
cyclopia in one family member to slight midline abnormal-
ities in another [71]. If the phenotype of mutant SHH-
associated holoprosencephaly were defined on narrowed
thresholds, there would undoubtedly be pure cases of
holoprosencephaly, with siblings showing the broader
spectrum of holoprosencephalic features. The mechanism
that leads to a phenotype with variable expressivity at
most loci is unknown; it is therefore possible that other
genetic variants and environmental factors may influence
the ASD phenotype when such a gene is mutated.
Conclusion
Given the diverse nature of the ASD phenotype, it
would be foolhardy to attempt to provide an absolute
cause for the disorder, whether from the perspective of
neuroscience, psychology or genetics. Therefore, an
architecture for ASD implying a causal role for de novo
mutations is not mutually exclusive to that of a model
with common variants. However, as the dissection of
this phenotype has progressed, it has become clear that
the role of common variants in the phenotype is far
lower than initially predicted.
Although ASD represents a continuum on the pheno-
typic level, this does not necessarily imply the presence
of a continuum at the genetic level. It is possible that
numerous monogenic, discrete genetic mutations can
produce a large spectrum of inextricable phenotypes.
T h i sw o u l dm a k ei ta l m o s ti m p o s s i b l et oc r e a t ep h e n o -
typic subsets of patients corresponding to the underlying
genetic mutation, even with the conceit of hindsight
provided after the genetic mutation is identified in a
particular patient. Evidence has already shown that de
novo mutations play a role in the development of ASD;
the current remaining question is whether a de novo
mutation model underlies the majority of the remaining
cases of idiopathic ASD.
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